T-cell exhaustion represents a significant hurdle in combating cancer and chronic infections, prompting the exploration of immune checkpoint blockades (ICB) like PD1 blockade as potential solutions. While ICB therapies have shown promise, their efficacy varies widely among patients and diseases, underscoring the need for a comprehensive understanding of T-cell exhaustion at the protein level. Dr. David Ezra Gordon, from Emory University School of Medicine, leads a research team delving into the intricate protein network governing immune responses. Their collaboration with the Mohammed Abdel-Hakeem Lab at Emory University has involved utilizing trapped ion mobility spectrometry (TIMS) to construct a detailed proteomic and phosphoproteomic landscape of exhausted T cells in vivo, particularly focusing on CD8⁺ T cells in the LCMV mouse model.
By employing cutting-edge mass spectrometry techniques, the Gordon Lab has not only confirmed known characteristics of T-cell exhaustion but has also unveiled previously undetected upregulated proteins that eluded transcriptomic analyses. Their innovative phosphoproteomic enrichment strategy, devoid of complex robotics, has shed light on the biochemical intricacies underlying T-cell exhaustion regulation. The webinar hosted by Dr. Gordon will showcase the efficacy of Bruker’s timsTOF Pro 2 technology, particularly its data-independent acquisition utilizing parallel accumulation serial fragmentation (dia-PASEF®) technology, in dissecting proteomic and phosphoproteomic profiles critical for understanding T-cell exhaustion.
Key Takeaways:
– Conservation analysis aids in identifying crucial phosphosites for subsequent investigations.
– Protein abundance analysis through TIMS exposes exhaustion-related protein expressions.
– Phosphoproteomics provides unparalleled insights into the biochemical landscape governing T-cell exhaustion.
– The live Q&A session following the webinar offers an opportunity to engage with experts and delve deeper into the discussed topics.
In the quest for more effective immunotherapies, understanding the molecular intricacies of T-cell exhaustion becomes paramount. With T-cell function restoration being pivotal in combating diseases like cancer, the proteomic and phosphoproteomic insights gleaned through advanced mass spectrometry methods provide a roadmap for uncovering novel immunotherapy targets. Dr. Gordon’s collaborative efforts exemplify the power of interdisciplinary research in deciphering the complex interplay of proteins governing immune responses, potentially paving the way for enhanced therapeutic interventions in the realm of cancer immunotherapy and chronic infection treatments.
The Gordon Lab’s groundbreaking work not only enriches the existing knowledge on T-cell exhaustion but also underscores the importance of integrating proteomic approaches with conventional transcriptomic analyses. By bridging these analytical methodologies, researchers can develop a more comprehensive understanding of the underlying mechanisms driving immune dysfunction. Through collaborations with both academic and industrial partners, the Gordon Lab exemplifies a model of research synergy aimed at propelling immunological discoveries forward and catalyzing the development of transformative therapeutic strategies.
As the scientific community delves deeper into the proteomic nuances of T-cell exhaustion, the potential for uncovering novel therapeutic targets grows exponentially. Leveraging state-of-the-art mass spectrometry technologies such as TIMS and dia-PASEF®, researchers can dissect the intricate protein networks orchestrating immune responses with unprecedented precision. The webinar led by Dr. Gordon serves as a beacon for researchers and clinicians alike, offering insights into the evolving landscape of immunotherapy and the pivotal role of proteomics in reshaping our approach to combating diseases characterized by T-cell exhaustion.
Read more on genengnews.com